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one or two enzymes. As the work progressed, he discovered more and more enzymes
with an essential role in the process. He might have been able to produce large amounts
of DNA polymerase, if molecular biological techniques had been available; but could
he have known that there are at least three DNA polymerases? The disciplines of
enzymology and molecular biology must necessarily complement one another, and
scientists must continue to study both. The need for such expertise is only emphasized
by the recent recognition ofthe catalytic activity ofsome forms ofRNA. Interestingly,
Kornberg talks of enzymes only as proteins and ignores the enzymatic functions of
RNA.
It's a good book, and it would have been better if Kornberg and his family and
colleagues had been more central. As it is, the detailed description ofscience overshad-
ows the human aspects ofa great career.
PHILIP K. BONDY
Department ofInternal Medicine
Yale University SchoolofMedicine
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World War II fundamentally changed popular American opinion of scientific
research. Many people considered that medical and technological breakthroughs
played a key role in securing the Allied victory. Increased funding for all types of
biomedical and scientific research was strongly supported by the public after the war.
Major improvements were expected in health care in the following decades, including
cures for cancer and heart disease.
As a result, Congress dramatically increased biomedical research funding in the
post-WW II years. The Financing ofBiomedical Research surveys the history of this
funding over the last four decades and analyzes the resulting trends and patterns. This
book divides these years into three distinct periods:
1. Rapid Growth (1950-1965): During this period the federal government became
the major funding source for biomedical research in the United States. The large
increase in federal funding more than offset a concomitant decline in private sources of
funds. These monies greatly contributed to a period of rapid growth and evolution in
the infrastructure of universities, medical schools, and teaching hospitals. Staff and
facilities were expanded to contribute to the vast accumulation of scientific and
technological knowledge. It is evident, therefore, that the U.S. government accom-
plished its goal ofdeveloping a large and productive biomedical research complex.
2. Slow Growth (1966-1982): During President Johnson's administration, the
effectiveness of financial support for biomedical research began to be questioned.
Although technological and scientific advances had been made, it was not clear that
patients had benefited in any significant fashion. It was clear, however, that many
Americans had been unable to take advantage of the advances in health care that had
been made. As a result, Congress was convinced to redirect biomedical research funds
toward the expansion and improvement of access to health care for the uninsured and
underinsured (through the creation of Medicare and Medicaid). Spiraling inflation
also contributed to the diminished flow of money to biomedical research and further
slowed its growth. In spite ofincreasing costs, the size ofthe traditional award actually
declined in constant dollars during this period.BOOK REVIEWS
3. Renewed Growth (1983-1987): During these years, the federal government
renewed its commitment to research. Reduced inflation also allowed Congress to
increase federal funding. Several differences, however, distinguish this period from the
earlier period of rapid growth in the 1950s. First, the federal government began to
emphasize the funding of basic scientific research rather than applied research and
development. Industry has consequently utilized its resources to increase funding for
applied research and development. Second, the federal government began to fund an
increasing proportion of research investigators in an attempt to support as many
talented people as possible.
One of the most important chapters analyzes the question of "How Many Dollars
Are Enough?" The discussion describes the effects of early ground-breaking basic
research on recent advances in applied research and development (R & D), including
clinical diagnosis and therapy. The possible economic returns of public R & D
spending on biomedical research was analyzed by Jeffery Harris, a physician and
economist at the Massachusetts Institute of Technology. He outlines the inherent
difficulties in even a complex cost-benefit approach to economic returns. The chapter
concludes that (1) the federal government should remain the primary funding source
for basic research in this country; (2) current academic research centers should be
targeted for increased support, as it is not practical to establish entirely new centers of
excellence in biomedical research; and (3) it is now desirable to encourage philanthropy
to strengthen funding ofcritical areas neglected by other funding mechanisms.
The remaining chapters deal with the role ofphilanthropy and academic medicine in
future prospects for biomedical research. A survey of ten academic health centers
showed a tendency to ignore the philanthropic dimension during the early years of
rapidly escalating federal funds. When federal funds were cut back in the early
eighties, however, the potential for increased funding from philanthropic sources was
recognized by almost all ofthe major medical research centers.
The last chapter is a timely discussion of "Open Issues on the Nation's Biomedical
Research Agenda." These issues include the loss of U.S. competitiveness in the world
economy and the lack of realistic cures for most diseases, including cancer, heart
disease, and AIDS. Also important are thegrowing levels ofinteraction between public
support, private universities, and the business-industrial communities. These business-
science-government interactions are, unfortunately, discussed only briefly; they are,
however, becoming increasingly important. For example, science is based upon the free
exchange of information. Business interests, however, often demand high levels of
secrecy until patent rights are obtained. This conflict illustrates only one of the
problems encountered in expanding the role ofjoint science-business ventures.
This book will be an excellent resource for all scientists and administrators interested
in how we came to support the structure of our billion-dollar biomedical research
agenda. In light ofthe huge federal deficit, and probable constricted funding for future
projects and scientists, the information overview obtained in this volume should be
increasingly useful.
MAUREEN A. SMITH
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